UK markets closed
  • FTSE 100

    7,500.89
    +34.98 (+0.47%)
     
  • FTSE 250

    20,338.96
    +93.53 (+0.46%)
     
  • AIM

    933.20
    +4.84 (+0.52%)
     
  • GBP/EUR

    1.1820
    +0.0002 (+0.02%)
     
  • GBP/USD

    1.2139
    -0.0064 (-0.52%)
     
  • BTC-GBP

    20,172.54
    +331.00 (+1.67%)
     
  • CMC Crypto 200

    574.64
    +3.36 (+0.59%)
     
  • S&P 500

    4,280.15
    +72.88 (+1.73%)
     
  • DOW

    33,761.05
    +424.38 (+1.27%)
     
  • CRUDE OIL

    91.88
    -2.46 (-2.61%)
     
  • GOLD FUTURES

    1,818.90
    +11.70 (+0.65%)
     
  • NIKKEI 225

    28,546.98
    +727.65 (+2.62%)
     
  • HANG SENG

    20,175.62
    +93.19 (+0.46%)
     
  • DAX

    13,795.85
    +101.34 (+0.74%)
     
  • CAC 40

    6,553.86
    +9.19 (+0.14%)
     

Global Human Recombinant DNA Market Analysis Report 2022-2027 Featuring Abbvie, Alexion Pharmaceuticals, Amgen, Eli Lilly, Merck & Co, Sanofi, & Takeda Pharmaceutical

·3-min read
Company Logo
Company Logo

Global Human Recombinant DNA Market

Global Human Recombinant DNA Market
Global Human Recombinant DNA Market

Dublin, Aug. 04, 2022 (GLOBE NEWSWIRE) -- The "Human Recombinant DNA: Global Markets" report has been added to ResearchAndMarkets.com's offering.

This report highlights the current and future market potential for human recombinant DNA and provides a detailed analysis of the competitive environment, regulatory scenario, drivers, restraints, opportunities, trends and key players in the market.

The report also provides market projections from 2022 through 2027. An in-depth discussion of strategic alliances, industry structures, competitive dynamics, and market forces are also provided.

Recombinant DNA technology (RDT) is essential for improving health conditions, primarily by developing new vaccines and pharmaceuticals. The treatment strategies are improved by developing diagnostics kits, monitoring devices and new therapeutic approaches. Additionally, many other industries such as agriculture are benefiting from the research conducted on genetically modified organisms (GMO), for example microorganisms that are considered clean fuel producers and bio degraders.

Advances in oncology research for discovering underlying molecular mechanisms of cancerous cells to develop novel therapeutics is benefitting the market. The rising number of advanced cancer cases worldwide has significantly increased the need for developing DNA damage-response drugs. These drugs can improve cancer survival by providing a selective and well-tolerated treatment approach.

Regulatory approvals that delay product marketing can adversely impact manufacturer revenues. Similarly, a delay in post-approval of a drug product for another therapeutic indication increases clinical trial costs and potentially affects the labeling and approval status of currently marketed products.

Report Includes

  • Estimation of the market size and analyses of global market trends, with data from 2020, 2021 with projections of compound annual growth rates (CAGRs) through 2026

  • Highlights of the market potential for human recombinant DNA, based on product, application, and region

  • Coverage of history and future of human recombinant DNA, and latest technological advancements of the industry

  • Identification of market drivers, restraints and other forces impacting the global market and evaluation of current market size and forecast

  • Coverage of regulatory landscape, product recalls, pipeline products, and discussion on future perspective, strategies, and developments of the industry

  • Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies and a relevant patent analysis

  • Company profiles of major players within the industry AbbVie Inc., Amgen Inc., Eli Lilly, Sanofi

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Overview

  • Homologous Recombination (Hr)

  • Targets for Cancer Therapy

Chapter 4 Impact of Covid-19 Pandemic

Chapter 5 Market Dynamics

  • Market Drivers

  • Increasing Incidences of Chronic Diseases

  • Growing Aging Population

  • Advancements in Manufacturing Technologies

  • Market Restraints

  • Price Controls

  • Entry of Biosimilars

  • Opportunities

  • Untapped Potential in Emerging Markets

Chapter 6 Market Breakdown by Product Type

  • Human Protein Replacements

  • Market Size and Forecast

  • Therapeutic Agents for Human Diseases

  • Market Size and Forecast

  • Vaccines

  • Types of Vaccines

  • Market Size and Forecast

Chapter 7 Market Breakdown by End-user

  • Biotechnology and Pharmaceutical Industry

  • Market Size and Forecast

  • Research Laboratories and Academic Institutes

  • Market Size and Forecast

Chapter 8 Market Breakdown by Region

  • Global Market by Region

  • North America

  • Europe

  • Asia-Pacific

  • Rest of the World

Chapter 9 Competitive Landscape

  • Overview

Chapter 10 Company Profiles

  • Abbvie Inc.

  • Alexion Pharmaceuticals

  • Amgen Inc.

  • Eli Lilly

  • Merck & Co. Inc.

  • Sanofi S.A.

  • Takeda Pharmaceutical Co Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/bzob5z

Attachment

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting